Table 2

Change from baseline to end of week 12 in primary and secondary variables in the subgroup of patients with PAH-CHD in Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (observed values)

PlaceboRiociguat 2.5 mg–maximumRiociguat 1.5 mg–maximum
nBaselineChange from baselinenBaselineChange from baselinenBaselineChange from baseline
6MWD (m)12360±590±4215369±78+39±60*8391±59+43±54†
PVR (dyn·s/cm5)111312±763−66±632131130±664−250±41071047±564−126±368
NT-proBNP (pg/mL)121573±1775−46±69713761±1172−164±317†71352±1350−872±1147†
WHO FC (%)12II–58%
Improved 8%
Stabilised 83%
Worsened 8%
Improved 21%
Stabilised 79%
Worsened 0%†
Improved 29%
Stabilised 71%
Worsened 0%†
Borg dyspnoea score124.3±2.7−0.1±2.4152.5±1.4−0.3±1.3*83.2±1.6−0.8±0.8†
EQ-5D score120.74±0.16−0.05±0.22150.78±0.15+0.03±0.18†80.74±0.08+0.09±0.14†
LPH score1240.4±20.0−0.1±15.81534.9±26.0−8.0±15.9†840.0±15.3−13.7±13.2†
  • Data are mean±SD unless otherwise indicated.

  • *Data missing for two patients.

  • †Data missing for one patient.

  • 6MWD, 6-min walking distance; CHD, congenital heart disease; EQ-5D, EuroQol Group 5-Dimensional Self-report Questionnaire (scores range from −0.6 to 1.0, with higher scores indicating a better quality of life); LPH, Living with Pulmonary Hypertension questionnaire (an adaptation of the Minnesota Living with Heart Failure Questionnaire; scores range from 0 to 105, with higher scores indicating worse quality of life); NT-proBNP, N-terminal of the prohormone of brain natriuretic peptide; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; WHO FC, WHO functional class.